Smarter leaders trust GlobalData

Data Insights Likelihood of Approval Analysis for Retinal Degeneration

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Retinal Degeneration overview

Retinal degeneration refers to a group of diseases that cause progressive damage to the cells of the retina, the light-sensitive tissue at the back of the eye crucial for vision. These conditions lead to a gradual loss of vision, which can range from mild to severe and can eventually result in blindness. There are several types of retinal degenerative diseases, including: Retinitis pigmentosa (RP): RP is a genetic disorder that affects the retina’s rod and cone cells, leading to a gradual loss of peripheral vision and difficulty seeing in low light. Over time, it can progress to tunnel vision or complete blindness. Age-related macular degeneration (AMD): AMD primarily affects the macula, the central part of the retina responsible for detailed central vision. It is more common in older individuals and can lead to blurred or distorted central vision, making it difficult to read or recognize faces. Stargardt disease: Stargardt disease is an inherited form of macular degeneration that usually manifests in childhood or adolescence. It causes progressive central vision loss due to the degeneration of the macula. Choroideremia: Choroideremia is a rare genetic disorder affecting the retina’s photoreceptor cells, leading to progressive vision loss that typically begins in childhood and worsens over time. Leber congenital amaurosis (LCA): LCA is a rare inherited disorder causing severe vision loss or blindness at birth or within the first few months of life. It affects the development of the retina and its ability to perceive light. Symptoms of retinal degeneration can vary based on the specific condition and its stage, but they often include reduced night vision, difficulty seeing in low light, loss of peripheral or central vision, and, in some cases, changes in color perception.

For a complete picture of PTSR and LoA scores for drugs in Retinal Degeneration, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.